Biological Significance of Anti–SARS-CoV-2 Antibodies

Lessons Learned From Progressive Multifocal Leukoencephalopathy

Navid Manouchehri, MD, Lawrence Steinman, MD, and Olaf Stuve, MD, PhD

Correspondence
Dr. Stuve
olaf.stuve@utsouthwestern.edu

Abstract

Objective
To discuss the pathogenic and diagnostic relevance of cellular and humoral immune responses against severe acute respiratory syndrome novel coronavirus (SARS-COV-2) and pertinent observations made in progressive multifocal leukoencephalopathy (PML).

Methods
Review of pertinent literature.

Results
There is at least 1 precedent for an antibody response against a viral pathogen that fails to provide host protection in the absence of immune-competent CD4$^+$ T cells. PML is an infection of the CNS caused by JC virus (JCV), which commonly occurs during treatment with the therapeutic monoclonal antibody natalizumab. In this context, the humoral immune response fails to prevent JCV reactivation, and elevated anti-JCV serum indices are associated with a higher PML incidence. The more relevant immune-competent cells in host defense against JCV appear to be T cells. T cell–mediated responses are also detectable in convalescing patients with SARS-COV-2 irrespective of the humoral immune response.

Conclusion
Based on pathogenic lessons learned from PML under natalizumab therapy, we suggest the incorporation of functional assays that determine neutralizing properties of SARS-CoV-2–specific antibodies. In addition, we outline the potential role of T-cell detection assays in determining herd immunity in a given population or in studying therapeutic responses to vaccines.

Glossary

GMFR = geometric mean fold rise; **GMT** = geometric mean titer; **Ig** = immunoglobulin; **IRIS** = immune reconstitution inflammatory syndrome; **JCV** = JC virus; **PML** = progressive multifocal leukoencephalopathy.

The emergence of the novel coronavirus severe acute respiratory syndrome novel coronavirus (SARS-COV-2) and the evolving coronavirus disease 2019 (COVID-19) pandemic have brought about an unprecedented surge of social, economic, and health burdens. There is growing recognition that achieving naturally acquired immunity on a population level will be associated with an unacceptable burden of mortality and disease-related comorbidities.[1] Consequently, the development of curative treatments or protective vaccines will be required for disease control.

Starting with smallpox inoculations more than 300 years ago, vaccines have been used to generate a protective immune response against a pathogen.[2] Vaccines are administered for primary or secondary disease prevention and contain immunogenic proteins, peptides, polysaccharides, or DNA or RNA that encode a dominant antigenic determinant. In the majority of human vaccines, serum antibodies against the inoculate or the pathogen have long served as a meaningful biomarker of immunogenicity and efficacy.

Currently, numerous vaccine candidates are being evaluated for their ability to generate SARS-CoV-2–specific immune responses. Recently reported preliminary results on 1 vaccine candidate showed a positive and dose-dependent serum immunoglobulin (Ig) G response of binding serum antibodies to the S-2P antigen of SARS-CoV-2 encoded by an RNA vaccine as measured by ELISA.[3] Studies have also demonstrated the vaccine-induced neutralizing activity of anti–SARS-CoV-2-IgG by using a pseudo-typed lentivirus reporter single-round-of-infection neutralization assay and live wild-type SARS-CoV-2 plaque reduction neutralization testing.[3]

In theory, naturally acquired immunity should accomplish the same goals as vaccination. Experiments in rhesus macaques (*Macaca mulatta*) provided evidence that in higher nonhuman primates, infection with SARS-CoV-2 results in detectable antibody responses and provides protective immunity to experimental animals.[4,5] However, these 2 observations may not be causally linked. For instance, it was shown by other investigators that naturally acquired humoral immunity in survivors may not be sustained beyond weeks or months.[6,7] Unfortunately, most studies that investigated immunologic biomarkers associated with SARS-CoV-2 exposure were inconsistent in their use of methodology and data acquisition. Assays that were used to measure serum IgM, IgG, or IgA responses include ELISA, lateral flow immune assays, and chemiluminescence immune assays. Data that were generated in these studies do not allow for an accurate association of humoral immune responses to SARS-CoV-2 and clinical disease activity.

Even more concerning, some studies appear to suggest an association between disease severity and higher anti–SARS-CoV-2 titers in COVID-19.[8–10] Plausible interpretations of this observation are (1) a lack of a neutralizing effect by anti–SARS-CoV-2 antibodies or (2) an antibody-dependent enhancement. Epidemiologic data from some of the hardest hit communities during the first wave of the COVID-19 pandemic appear to support this interpretation: With their corresponding outbreaks almost over, seroprevalence studies suggest a dissociation between the rate of disease propagation and seroconversion in these communities.[11,12] Taken together, these observations call into question a universally protective anti–SARS-CoV-2 antibody response.

There is at least 1 precedent for an antibody response against a viral pathogen that fails to provide host protection. Progressive multifocal leukoencephalopathy (PML) is an infection of the CNS caused by the human polyoma virus JC virus (JCV). PML is almost exclusively observed in individuals with severe and prolonged immunosuppression. One setting that allows PML to occur is treatment with the humanized recombinant monoclonal antibody natalizumab, which binds to α4-integrin and prevents its interaction with its ligands vascular cell adhesion protein 1 in the CNS and mucosal addressin cell adhesion molecule 1 in the gastrointestinal tract.[13] Natalizumab reduces the ability of leukocytes to migrate into the brain and spinal cord, creating a relatively immune-deficient microenvironment that is likely permissive for JCV activation to occur.

A prerequisite for PML is an infection with JCV, which occurs very commonly in most populations and which is typically followed by a period of viral latency. Upon the primary infection with JCV, the virus is recognized, and a cellular[14,15] and humoral[16,17] adaptive immune response is generated. Anti-JCV antibodies are detectable in 50%–85% of all adults.[18–20] Given that almost all patients under natalizumab who develop PML are anti-JCV IgG positive, it is currently thought that the humoral immune response is not able to prevent reactivation of JCV and the development of PML.[21] In fact, although causality has not been demonstrated, higher anti-JCV serum indices are associated with a higher incidence of PML under natalizumab.[22] We will argue below that the more relevant immune-competent cells in host defense against JCV appear to be T cells.[14,15]

A critical role for T cells reactive to JCV was also demonstrated in patients with MS who developed PML and subsequently immune reconstitution inflammatory syndrome (IRIS) after natalizumab cessation. IRIS was characterized

immunologically mostly in individuals infected with the HIV. Following the introduction of antiretroviral therapies to clinical practice, an increase in the number of circulating CD4[+] T cells was associated with an increased incidence in organ specific inflammation that was not specific to the CNS.[23] Some patients also developed PML as a manifestation of IRIS.[24] Aly et al.[25] performed a histopathologic evaluation of biopsy material from patients with MS who developed PML under natalizumab and IRIS after treatment cessation and showed a prominent T-cell infiltrate driven mostly by CD4[+] T cells. In addition, B lymphocytes, plasma cells, and monocytes were also detected in affected tissue. Within the CSF, there were high levels of anti-JCV antibodies. Brain-infiltrating CD4[+] T cells were highly reactive to peptide determinants from several JCV proteins, particularly the major capsid protein VP1. Although these findings strongly suggest that JCV-specific CD4[+] T cells play an important role in IRIS, the functional contribution of B-cell subsets or anti-JCV antibodies was not clarified in this study or by other investigators. Of interest, the same investigators recently investigated the effects of natalizumab on intrathecal antibodies to viral pathogens and demonstrated that anti-JCV IgG was detectable in 20% of patients with MS before natalizumab initiation.[26] Once natalizumab was administered, the frequency of patients with intrathecal anti-JCV IgG declined. Total CSF IgG and IgM levels also diminished significantly. Because natalizumab substantially reduces the number of intrathecal T cells,[27,28] and the presence of intrathecal anti-JCV IgG, one may argue that both are relevant in host defense against JCV. However, although a reduction in the number of T cells is an event that can be ascertained almost immediately after natalizumab administration, a decline in CSF IgM and IgG levels appears to be a later phenomenon, and at least in 1 study, this was not demonstrated after 14 months of therapy.[29] Many patients with MS on natalizumab therapy have been diagnosed with PML in the first year of treatment, which would favor our argument that the cellular antiviral response is essential for the prevention of PML.

In summary, the humoral acquired immune response against JCV is a reliable diagnostic and prognostic biomarker, but it fails to correlate with host defense in the absence of Ag-specific cellular immune response. Although this phenomenon is incompletely understood, the generation of anti-JCV IgG may present a forme fruste of an adaptive immune response.

A similar role for SARS-CoV-2 binding serum antibodies is conceivable in infected patients, in whom the infection can lead to lymphopenia in patients with a severe disease cause [30,31] or in recipients of anti–SARS-CoV-2 vaccines in whom the vaccine fails to mount a robust T-cell response. Ongoing clinical trials assess humoral immune responses, including the longitudinal geometric mean titer (GMT) of SARS-CoV-2–specific neutralizing antibody, the geometric mean fold rise (GMFR) of SARS-CoV-2–specific neutralizing antibody, quantified levels or GMT of S protein–specific binding antibody, and the GMFR of S protein–specific binding antibody (for instance: clinicaltrials.gov/ct2/show/NCT04470427). Although using assays that assess the neutralizing capabilities of anti–SARS-CoV-2-IgG is paramount for quality control, other adaptive cellular immune responses should also be interrogated. With exception to adaptive immune responses against complex sugars, antibody isotype switching from IgM to IgG does not occur without the involvement of CD4[+] T helper cell reactive to the same antigen.[32,33]

Of interest, studies that investigated adaptive T-cell responses against anti–SARS-CoV-2 have yielded some perhaps unexpected results. These investigators detected SARS-CoV-2–reactive CD4[+] T helper cells and CD8[+] cytotoxic T cells in patients with a known exposure to SARS-CoV-2, but also in individuals in whom blood samples were obtained years before the onset of COVID-19,[34] or in up to 50% of study participants without a known viral exposure.[35–38] T-cell receptor promiscuity has been described for CD4[+39] and CD8[+] T cells,[40] and the aforementioned observations likely reflect memory T-cell reactivity to common cold coronavirus.

As stated above, for B-cell subsets to generate an antigen-specific antibody response, CD4[+] T cell help is required for most types of antigen. Thus, it appears counterintuitive to believe that an amplified humoral immune response would be associated with impaired CD4[+] T-cell function. However, the composition of CD4[+] T cells in pertinent tissues may affect quantitative antibody responses. For instance, interleukin-4 is a major driver of T-cell cross-activation of B cells that lead to antibody expression and maturation.[41] Also, the expression of CD40L by CD4[+] T cells is critical for the same purpose,[41] and one could envision that low expression of this costimulatory molecule may affect B-cell cross-activation.

In conclusion, serum-based detection assays for anti–SARS-CoV-2 binding antibodies may not prove sufficient in ascertaining herd immunity in a given population or in studying therapeutic responses to vaccines. Functional assays will be required to determine neutralizing properties of SARS-CoV-2–specific antibodies. In addition, it may be meaningful to assess cellular adaptive immune responses against SARS-CoV-2 and specifically against pertinent spike peptides.[34,35,37,38] The detection of antigen-reactive T cells by customized HLA tetramers is considerably more complex than antibody detection assays with regard to assay verification and implementation. Furthermore, vaccine recipients would have to be HLA genotyped. Other methods, including activation induced marker assays, have been used to detect antigen-specific T cells in blood and lymphoid tissues,[42–44] including T cells reactive to SARS-CoV-2 epitopes.[45] A pharmacologically and biologically plausible diagnostic approach will enable the medical community to overcome the challenges of the COVID-19 pandemic and will inform on diagnostic strategies for future pandemics.

Appendix Authors

Name	Institution	Contribution
Navid Manouchehri, MD	University of Texas Southwestern Medical Center, TX	Conceptualized the study; collected data; drafted the manuscript; and revised the final manuscript
Lawrence Steinman, MD	Stanford University, Stanford, CA	Conceptualized the study; collected data; drafted the manuscript; and revised the final manuscript
Olaf Stuve, MD	University of Texas Southwestern Medical Center, TX	Conceptualized the study; collected data; drafted the manuscript; and revised the final manuscript

References

1. Banerjee A, Pasea L, Harris S, et al. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. Lancet 2020;395:1715–1725.
2. Plotkin S. History of vaccination. Proc Natl Acad Sci U S A 2014;111:12283–12287.
3. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020;383:1920–1931.
4. Munster VJ, Feldmann F, Williamson BN, et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature 2020;585:268–272.
5. Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 2020;369:eabc4776.
6. Edridge AW, Kaczorowska J, Hoste ACR, et al. Coronavirus protective immunity is short-lasting. medRxiv, 2020;2005:2011.
7. Seow J, Graham C, Merrick B, et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. medRxiv, 2020;2007.
8. Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol 2020;20:339–341.
9. Tan W, et al. Viral kinetics and antibody responses in patients with COVID-19. medRxiv, 2020.2003.2024.20042382 (2020). doi: 101101/2020.03.24.20042382.
10. Jiang HW, Li Y, Zhang HN, et al. SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses. Nat Commun 2020;11:3581.
11. Pollan M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020;396:p535–p544.
12. Rostami A, Sepidarkish M, Leeflang MMG, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect 2020;S1198-743X(20)30651-0.
13. Shirani A, Stuve O. Natalizumab: perspectives from the bench to bedside. Cold Spring Harb Perspect Med 2018;8:a029066.
14. Koralnik IJ, Du Pasquier RA, Letvin NL. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol 2001;75:3483–3487.
15. Du Pasquier RA, Clark KW, Smith PS, et al. JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy. J.Neurovirol. 2001;7:318–322.
16. Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 1973;127:467–470.
17. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003;71:115–123.
18. Stolt A, Sasnauskas K, Koskela P, Lehtinen M, Dillner J. Seroepidemiology of the human polyomaviruses. J Gen Virol 2003;84:1499–1504.
19. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. Plos Pathog 2009;5:e1000363.
20. Gossai A, Waterboer T, Nelson HH, et al. Seroepidemiology of human polyomaviruses in a US population. Am J Epidemiol 2016;183:61–69.
21. Koralnik IJ. New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol 2004;17:365–370.
22. Ho PR, Koendgen H, Campbell N, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol 2017;16:925–933.
23. Zegans ME, Walton RC, Holland GN, O'Donnell JJ, Jacobson MA, Margolis TP. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1998;125:292–300.
24. Vendrely A, Bienvenu B, Gasnault J, Thiebault JB, Salmon D, Gray F. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol 2005;109:449–455.
25. Aly L, Yousef S, Schippling S, et al. Central role of JC virus-specific CD4+-lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain 2011;134:2687–2702.
26. Largey F, Jelcic I, Sospedra M, Heesen C, Martin R, Jelcic I. Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS. Neurol Neuroimmunol Neuroinflamm 2019;6:e621. doi: 10.1212/NXI.0000000000000621.
27. Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743–747.
28. Stuve O, Yousef S, Schippling S, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch.Neurol. 2006;63:1383–1387.
29. Stüve O, Cravens PD, Frohman EM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 2009;72:396–401.
30. Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care 2020;8:36.
31. Zhao Q, Meng M, Kumar R, et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis. Int J Infect Dis 2020;96:131–135.
32. Shapira SK, Jabara HH, Thienes CP, et al. Deletional switch recombination occurs in interleukin-4-induced isotype switching to IgE expression by human B cells. Proc Natl Acad Sci U S A 1991;88:7528–7532.
33. Cocks BG, de Waal Malefyt R, Galizzi JP, de Vries JE, Aversa G. IL-13 induces proliferation and differentiation of human B cells activated by the CD40 ligand. Int Immunol 1993;5:657–663.
34. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 2020;181:1489–1501.e15.
35. Weiskopf D, Schmitz KS, Raadsen MP, et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol 2020;5:eabd2071.
36. Braun J, Loyal L, Frentsch M, et al. Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. medRxiv 2020;2004.
37. Bert NL, Tan AT, Kunasegaran K, et al. Different pattern of pre-existing SARS-COV-2 specific T cell immunity in SARS-recovered and uninfected individuals. Nature 2020;584:457–462.
38. Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 2020;183:158–168.e14.
39. Sospedra M, Muraro PA, Stefanová I, et al. Redundancy in antigen-presenting function of the HLA-DR and -DQ molecules in the multiple sclerosis-associated HLA-DR2 haplotype. J Immunol 2006;176:1951–1961.
40. Zügel U, Schoel B, Yamamoto S, Hengel H, Morein B, Kaufmann SH. Cross-recognition by CD8 T cell receptor alpha beta cytotoxic T lymphocytes of peptides in the self and the mycobacterial hsp60 which share intermediate sequence homology. Eur J Immunol 1995;25:451–458.
41. Choi MS, Brines RD, Holman MJ, Klaus GG. Induction of NF-AT in normal B lymphocytes by anti-immunoglobulin or CD40 ligand in conjunction with IL-4. Immunity 1994;1:179–187.
42. Dan JM, Lindestam Arlehamn CS, Weiskopf D, et al. A cytokine-independent approach to identify antigen-specific human germinal center T follicular helper cells and rare antigen-specific CD4+ T cells in blood. J Immunol 2016;197:983–993.
43. Havenar-Daughton C, Reiss SM, Carnathan DG, et al. Cytokine-independent detection of antigen-specific germinal center T follicular helper cells in immunized nonhuman primates using a live cell activation-induced marker technique. J Immunol 2016;197:994–1002.
44. Reiss S, Baxter AE, Cirelli KM, et al. Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells. PLoS One 2017;12:e0186998.
45. Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science 2020;370:89–94.